Evaluation of the Presence of Deletion of the Long Arm of Chromosome 20 in Multiple Myeloma

Abstract Objectives To determine the occurrence of deletion of the long arm of chromosome 20 in cytogenetic studies of multiple myeloma patients. Methods A retrospective study of cytogenetic studies from patients with a diagnosis of multiple myeloma was undertaken to determine the most common cytoge...

Full description

Saved in:
Bibliographic Details
Published in:American journal of clinical pathology 2018-09, Vol.150 (suppl_1), p.S114-S114
Main Authors: Van Rheeden, Richard, Koslosky, Lori, Dunham, Timothy
Format: Article
Language:English
Subjects:
Chromosome 20
Chromosome 5
Chromosome deletion
Chromosomes
Cytogenetics
Diagnosis
Health risk assessment
Multiple myeloma
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objectives To determine the occurrence of deletion of the long arm of chromosome 20 in cytogenetic studies of multiple myeloma patients. Methods A retrospective study of cytogenetic studies from patients with a diagnosis of multiple myeloma was undertaken to determine the most common cytogenetic abnormalities identified. A total of 456 patients with at least four cytogenetic studies from the past 10 years were reviewed. Results Of these patients, 135 (29.6%) exhibited abnormal chromosomes within the period of the review. Of the abnormal results, 33 (24.4%) had an abnormality involving one chromosome, and 101 (74.4%) had abnormalities involving more than one chromosome. One abnormal result was determined to be constitutional (.8%) of the abnormal and 0.22% of the total patients. The most common single-chromosome abnormality was a deletion of the long arm of chromosome 20. A total of 17 of the 33 patients (51.5%) exhibited this abnormality. The next most numerous of this type of abnormality included four (12.1%) patients with a deletion of the long arm of 13. Two (6%) patients had a deletion of the long arm of chromosome 5. Conclusion Further investigation is required to determine if these deletions are related to the initial diagnosis of multiple myeloma or are a secondary treatment-induced myeloid disorder.
ISSN:0002-9173
1943-7722
DOI:10.1093/ajcp/aqy097.276